About the Company
We do not have any company description for Jasper Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Jasper Therapeutics, Inc.
Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of ...
Jasper Therapeutics Faces Business Risks Amid Clinical Trial Delays and Competitive Pressures
Jasper Therapeutics, Inc. (JSPR) has disclosed a new risk, in the Innovation / R&D category.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing ...
Jasper Therapeutics Reports Promising Q2 2025 Results
Jasper Therapeutics, Inc. ( ($JSPR) ) has released its Q2 earnings. Here is a breakdown of the information Jasper Therapeutics, Inc. presented to ...
Jasper Therapeutics to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel ...
Jasper Therapeutics, Inc. Announces Reverse Stock Split
Alex Gray (investors) Jasper Therapeutics 650-549-1454 agray@jaspertherapeutics.com Lauren Barbiero (media)Real Chemistry646-564-2156 lbarbiero@realchemistry.com Source: Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing ...
REDWOOD CITY, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (JSPR) (“Jasper”), a biotechnology company focused on developing novel antibody therapies targeting c-Kit ...
Jasper Therapeutics Announces Further Expansion of Clinical Program in ...
Jasper Therapeutics 650-549-1454 agray@jaspertx.com Joyce Allaire (investors) LifeSci Advisors 617-435-6602 jallaire@lifesciadvisors.com Lauren Walker (media) Real Chemistry 646-564-2156 ...
Jasper Therapeutics Closes Transaction With Amplitude Healthcare ...
Following the closing, the combined company will operate as Jasper Therapeutics, Inc. and, on or about September 27, 2021, its shares of voting common stock and warrants are expected to begin ...
Jasper Therapeutics, Inc.: Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody ...
Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq ...
Each Option was granted pursuant to the Jasper Therapeutics, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan, as approved by the compensation committee of Jasper’s board of ...
Similar Companies
Loading the latest forecasts...